Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Elanco Animal Health Incorporated showed promising performance in its second quarter of 2024, demonstrating consistent operational results and strategic progress in various key areas.</li><li>With a fourth consecutive quarter of underlying revenue growth, the company has displayed resilience and growth in its core segments.</li><li>The adjusted EBITDA and adjusted EPS metrics surpassed the estimates by achieving higher figures than projected in previous guidance, indicating efficient operational and cost management.</li></ul>

Elanco Animal Health Incorporated showed promising performance in its second quarter of 2024, demonstrating consistent operational results and strategic progress in various key areas.With a fourth consecutive quarter of underlying revenue growth, the company has displayed resilience and growth in its core segments.The adjusted EBITDA and adjusted EPS metrics surpassed the estimates by achieving higher figures than projected in previous guidance, indicating efficient operational and cost management.

Elanco Animal Health: Leveraging Portfolio Synergy & Market Access To Catalyze Growth! - Major Drivers

<ul><li>Elanco Animal Health Incorporated has demonstrated a strong start to 2024 with positive developments in multiple areas of its business, despite facing some challenges.</li><li>The company has achieved encouraging financial and operational results, underscored by success in its strategic initiatives aimed at enhancement and innovation.</li><li>Starting with the financials, Elanco surpassed its revenue, adjusted EBITDA, and adjusted EPS guidance for Q1 2024, indicating robust underlying business performance.</li></ul>

Elanco Animal Health Incorporated has demonstrated a strong start to 2024 with positive developments in multiple areas of its business, despite facing some challenges.The company has achieved encouraging financial and operational results, underscored by success in its strategic initiatives aimed at enhancement and innovation.Starting with the financials, Elanco surpassed its revenue, adjusted EBITDA, and adjusted EPS guidance for Q1 2024, indicating robust underlying business performance.

Elanco Animal Health Incorporated: Will The Accelerated Global Rollout of Zenrelia Boost Its Top-Line? - Major Growth Drivers

External reports (aggregated public sources), Value Investors Club

Value Investors Club

External reports (aggregated public sources)

<ul><li>Elanco Animal Health Inc is a leading global provider of pharmaceutical products for Companion Animals and Farm Animals</li><li>Stock has declined around 50% since early 2020 due to challenges such as the Covid pandemic and disappointing guidance for FY 2022</li><li>Activist engagement from Sachem Head and a stock price trading at a wide discount to peers make Elanco an intriguing investment opportunity for those willing to weather industry turbulence</li></ul><p><em>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.</em></p>

Elanco Animal Health Inc is a leading global provider of pharmaceutical products for Companion Animals and Farm AnimalsStock has declined around 50% since early 2020 due to challenges such as the Covid pandemic and disappointing guidance for FY 2022Activist engagement from Sachem Head and a stock price trading at a wide discount to peers make Elanco an intriguing investment opportunity for those willing to weather industry turbulenceThis content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Elanco Animal Hlth Inc (ELAN) - Wednesday, Feb 7, 2024

<ul><li>In Q4 2023, Elanco Animal Health reported a 5% constant currency revenue growth, driven by innovations, the strength of the farm animal business, improved conditions in the European Pet Health retail market, and increased pricing.</li><li>The strong performance in 2023 indicates that the company's innovation, portfolio, and productivity strategy are working, leading to confidence in the potential success of future investments.</li><li>Going into 2024, the company aims to focus on three priorities: sustained revenue growth, innovation, and improved cash conversion.</li></ul>

In Q4 2023, Elanco Animal Health reported a 5% constant currency revenue growth, driven by innovations, the strength of the farm animal business, improved conditions in the European Pet Health retail market, and increased pricing.The strong performance in 2023 indicates that the company's innovation, portfolio, and productivity strategy are working, leading to confidence in the potential success of future investments.Going into 2024, the company aims to focus on three priorities: sustained revenue growth, innovation, and improved cash conversion.

Elanco Animal Health: Initiation Of Coverage - A Story Of Concentration on Pet Health and Livestock Sustainability! - Major Drivers

Global Healthcare Analyst

Tina Banerjee

Event-Driven

<ul>
<li>
<a href="https://www.smartkarma.com/entities/dechra-pharmaceuticals-plc" target="_blank" data-smartkarma-citation="entities:21908:1" rel="noopener">Dechra Pharmaceuticals (DPH LN)</a> received an offer from the Swedish private equity firm EQT regarding a possible all-cash deal, where Dechra shareholders would receive £40.70 per ordinary share in cash.</li>
<li>Right after the announcement, Dechra shares surged 33%. The shares are currently trading at £37.66, implying 10% upside potential.</li>
<li>Without EQT offer, based on current financial performance, Dechra has a bleak outlook. Currently, Dechra has average target price of £39.39, implying a spread of just ~5%.</li>
</ul>



Dechra Pharmaceuticals (DPH LN) received an offer from the Swedish private equity firm EQT regarding a possible all-cash deal, where Dechra shareholders would receive £40.70 per ordinary share in cash.
Right after the announcement, Dechra shares surged 33%. The shares are currently trading at £37.66, implying 10% upside potential.
Without EQT offer, based on current financial performance, Dechra has a bleak outlook. Currently, Dechra has average target price of £39.39, implying a spread of just ~5%.


Dechra Pharmaceuticals (DPH LN): Best Case Scenario Offers 10% Upside Potential

United States

Elanco Animal Health Incorporated operates as an animal health care company. The Company develops, manufactures, and markets products for companion and food animals. Elanco Animal Health serves clients worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Elanco Animal Health (ELAN US)

Elanco Animal Health: Leveraging Portfolio Synergy & Market Access To Catalyze Growth! - Major Drivers

Elanco Animal Health Incorporated showed promising performance in its second quarter of 2024, demonstrating consistent operational results and...

Baptista Research

Elanco Animal Health Incorporated: Will The Accelerated Global Rollout of Zenrelia Boost Its Top-Line? - Major Growth Drivers

Elanco Animal Health Incorporated has demonstrated a strong start to 2024 with positive developments in multiple areas of its business, despite...

Baptista Research

Elanco Animal Hlth Inc (ELAN) - Wednesday, Feb 7, 2024

Activist engagement from Sachem Head and a stock price trading at a wide discount to peers make Elanco an intriguing investment opportunity for...

Value Investors Club

Elanco Animal Health: Initiation Of Coverage - A Story Of Concentration on Pet Health and Livestock Sustainability! - Major Drivers

In Q4 2023, Elanco Animal Health reported a 5% constant currency revenue growth, driven by innovations, the strength of the farm animal business,...

Baptista Research

Dechra Pharmaceuticals (DPH LN): Best Case Scenario Offers 10% Upside Potential

Dechra received takeover offer from private equity firm EQT for £40.70 per share all-cash deal. Current price implies ~10% spread. EQT has until 11...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)